Abstract
The aims of the UKW2 study were: (1) to further refine treatment for stage I and II favourable histology (FH) patients; (2) to consolidate the UKW1 results for stage III FH patients; (3) to improve the outlook for patients with inoperable primary tumours and those patients with stage IV and unfavourable histology disease. Treatment consisted of primary nephrectomy, wherever possible, followed by chemotherapy and radiotherapy, as dictated by stage and histology. Treatment was refined successfully for stage I and II FH patients. The 4-year event-free survival for these two groups was 94% and 91%, respectively. Stage III FH patients had a 4-year event free survival of 84%. The outlook for patients with clear cell sarcoma of the kidney is as good as for patients with favourable histology, whilst that for patients with anaplastic or rhabdoid variants remains poor. The outlook for the majority of children with Wilms’ tumour is now excellent. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Brennan P & Silman A (1992) Statistical methods for assessing observer variability in clinical measures. BMJ 304: 1491–1494
D’Angio GJ, Evans AE, Breslow N, Beckwith B, Bishop H, Feigl P, Goodwin W, Leape LL, Sinks LF, Sutow W, Tefft M & Wolff J (1976) The treatment of Wilms’ tumour. Results of the first National Wilms’ tumour study. Cancer 38: 633–646
D’Angio GJ, Evans AE, Breslow N, Beckwith B, Bishop H, Farewell V, Goodwin W, Leape L, Palmer N, Sinks L, Sutow W, Tefft M & Wolff J (1981) The treatment of Wilms’ tumour: results of the second National Wilms’ tumour study. Cancer 47: 2302–2311
D’Angio GJ, Breslow N, Beckwith JB, Evans AE, Baum H, de Lorimier A, Fernbach D, Hrabovsky E, Jones B & Kelalis P (1989) The treatment of Wilms’ tumour. Results of the third National Wilms’ tumour study. Cancer 64: 349–360
De Kraker J, Lemerle J, Voute PA, Zucker JM, Tournade MF & Carli M (1990) Wilms’ tumour with pulmonary metastases at diagnosis: The significance of primary chemotherapy. J Clin Oncol 8: 1187–1190
Godzinski J, Tournade MF, De Kraker J, Ludwig R, Weirich A, Voute PA, Burgers JM, Habrand JL, Sandstedt B & Ducourtieux M (1999) The role of preoperative chemotherapy in the treatment of nephroblastoma: the SIOP experience. Semin Urol Oncol 17: 28–32
Green DM & Coppes MJ (1995) Future directions in clinical research in Wilms’ tumor. Hematol Oncol Clin North Am 9: 1329–1339
Green DM, Finklestein JZ, Norkool P & D’Angio GJ (1988) Severe hepatic toxicity after treatment with single-dose dactinomycin and vincristine. Cancer 62: 270–273
Green DM, Breslow NE, Evans I, Moksness J, Finklestein JZ, Evans AE & D’Angio GJ (1995) Relationship between dose schedule and charges for treatment on national Wilms’ tumor study 4. A report from the National Wilms’ Tumor Study Group. J Natl Cancer Inst 19: 21–25
Green DM, D’Angio GJ, Beckwith JB, Breslow NE, Grundy PE, Ritchey ML & Thomas PR (1996 a) Wilms’ Tumor. CA Cancer J Clin 46: 46–63
Green DM, Breslow NE, Evans I, Moksness J & D’Angio GJ (1996 b) Treatment of children with stage IV favorable histology Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. Med Pediatr Oncol 6: 147–152
Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy P, Thomas PR, Kim T, Shochat S, Haase G, Ritchey M, Kelalis P & D’Angio GJ (1998) Effect of duration of treatment on treatment outcome and cost of treatment for Wilms’ tumour: a report from the National Wilms’ Tumour Study Group. J Clin Oncol 16: 3744–3751
Kaplan EL & Meier P (1958) Non-parametric estimation from incomplete observations. Journal of the American Statistical Association 53: 457–481
Kumar R, Fitzgerald R & Breatnach F (1998) Conservative management of bilateral Wilms’ tumor: results of the United Kingdom Children’s Cancer Study Group. J Urol 160: 1450–1453
Lennox EL, Stiller CA, Morris-Jones PH & Kinnier-Wilson LM (1979) Nephroblastoma: treatment during 1970–73 and the effect on survival of inclusion in the first MRC trial. BMJ 2: 567–569
Lipshultz SE, Colan SD, Gelber RD, Perez-Attayde AR, Sallan SE & Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in children. New Engl J Med 324: 808–815
Ludwig R, Weirich A, Hofman WJ & Waldherr R (1992) Veno-occlusive disease as a hepatotoxic side-effect of the Nephroblastoma SIOP-9 protocol: preliminary results of the German Group. Med Pediatr Oncol 20: 434
Morris-Jones P, Marsden HB, Pearson D & Barnes J (1987) MRC second nephroblastoma trial, 1974–78: long-term results. SIOP Proceedings 1987, SIOP: Jerusalem
Pachnis A, Pritchard J, Gaze M, Levitt G & Michalski AM (1998) Radiotherapy omitted in the treatment of selected children under 3 years of age with stage III favorable histology Wilms’ tumor. Med Pediatr Oncol 31: 150–152
Peto R, Pike C, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J & Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 35: 1–37
Pritchard J, Imeson J, Barnes J, Cotterill S, Gough D, Marsden HB, Morris-Jones P & Pearson D (1995) Results of the United Kingdom Children’s Cancer Study Group (UKCCSG) First Wilms’ Tumor Study (UKW-1). J Clin Oncol 13: 124–33
Raine J, Bowman A, Wallendszus K & Pritchard J (1991) Hepatopathy-thrombocytopenia syndrome. A complication of actinomycin-D therapy for Wilms’ tumours. J Clin Oncol 9: 268–273
Sorensen K, Levitt G, Sebag-Montefiore D, Bull C & Sullivan I (1995) Cardiac function in Wilms’ tumour survivors. J Clin Oncol 13: 1546–1556
Tournade MF, Com-Nogue C, Voute PA, Lemerle J, de Kraker J, Delemarre,, Burgers M, Habrand JL, Moorman CGM, Burger D, Rey A, Zucker JM, Carli M, Jereb B, Bey P, Gauthier F & Sandstedt B (1993) Results of the sixth International Society of Paediatric Oncology Wilms’ tumor trial and study: a risk adapted approach in Wilms’ tumor. J Clin Oncol 11: 1014–1023
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Mitchell, C., Jones, P., Kelsey, A. et al. The treatment of Wilms' tumour: results of the United Kingdom Children's Cancer Study Group (UKCCSG) second Wilms' tumour study. Br J Cancer 83, 602–608 (2000). https://doi.org/10.1054/bjoc.2000.1338
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1338
Keywords
This article is cited by
-
Rationale for the treatment of children with CCSK in the UMBRELLA SIOP–RTSG 2016 protocol
Nature Reviews Urology (2018)
-
HER2/neu Expression: A Predictor for Differentiation and Survival in Children With Wilms Tumor
Pathology & Oncology Research (2010)
-
Current Management of Wilms’ Tumor
Current Urology Reports (2010)